Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel) - 11/09/11
Abstract |
OBJECTIVE: Our goal was to determine the effects of a repeated course of the gonadotropin-releasing hormone agonist nafarelin on symptoms and signs of endometriosis and lumbar and distal radius bone mineral density. STUDY DESIGN: Forty-five women previously treated for 6 months with nafarelin, who had recurrent symptoms and signs of endometriosis, received 400 mcg/day of nafarelin intranasally for 3 months. Efficacy was evaluated by changes in severity of symptoms and signs. Lumbar bone mineral density was measured by dual-energy x-ray absorptiometry and distal radius bone mineral density by single-photon absorptiometry. Bone mineral density was also measured in 10 control volunteers. RESULTS: Repeated 3-month treatment significantly alleviated recurrent symptoms and signs of endometriosis. Lumbar bone mineral density decreased significantly by a mean of 2% at the end of treatment; this loss was restored within 3 to 6 months after treatment completion. No bone mineral density decline occurred in the radius. Bone mineral density changes in the control group were statistically insignificant. CONCLUSIONS: A repeated 3-month course of nafarelin treatment significantly relieved recurrent endometriotic symptoms and signs without sustained loss of bone mineral density.(Am J Obstet Gynecol 1997;177:8)
Le texte complet de cet article est disponible en PDF.Keywords : Nafarelin, endometriosis, gonadotropin-releasing hormone, bone mineral density
Plan
 | From the Fertility Physicians of Northern Californiaa and Syntex Research,b Palo Alto; the Department of Gynecology and Obstetrics, Stanford University School of Medicinec; the Department of Obstetrics and Gynecology, University Hospital, Londond; the Department of Obstetrics and Gynecology, Falun Hospitale; the Department of Obstetrics and Gynecology, Sodertalje Hospitalf; and the Department of Orthopedics, Huddinge Hospital.g |
| Supported in part by a grant from Syntex Laboratories, Palo Alto, California, and by G.D. Searle & Co., Skokie, Illinois. |
 | Reprint requests: Reprint requests: G. David Adamson, MD, Fertility Physicians of Northern California, 540 University Ave., Suite 200, Palo Alto, CA 94301. |
| 6/1/84233 |
Vol 177 - N° 6
P. 1413-1418 - décembre 1997 Retour au numéro
Article précédent
- The association of sexual abuse with pelvic pain complaints in a primary care population
- Denise J. Jamieson, John F. Steege
- Congenital cervical atresia: Report of seven cases and review of the literature
- Victor Y. Fujimoto, J.Heath Miller, Nancy A. Klein, Michael R. Soules
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?